FDA Recommends Narrowed Indication For EDAP’s Ablatherm-HIFU
This article was originally published in The Gray Sheet
Executive Summary
The agency sent EDAP TMS a not-approvable letter for its high intensity focused ultrasound device, asking the company to narrow its sought prostate cancer indication and provide additional safety and efficacy data by next spring.